venBio Global Strategic Fund IV reports Attovia Therapeutics common share acquisition valued at $6.5 million
ATTO•venBio Global Strategic Fund IV increases Attovia stake
- venBio Global Strategic Fund IV, L.P., a 10% owner of Attovia Therapeutics, reported a rise in its common stock stake to 4,181,367 shares.
- The increase included 382,352 shares bought at $17 per share.
- The filing also reflected additional shares received via conversions of preferred stock into common stock.
Related News
Summit Midstream Q2 FY26 returns to profit at $4.6 million; adjusted EBITDA rises 12% vs Q1 to $60.7 million
SMC•
Arq Q2 FY26 adjusted EBITDA rises 59% to $5.8 million; revenue increases 5% to $29.9 million
ARQ•
